Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Novacyt de volgende biotech raket!
Volgen
DeZwarteRidder schreef op 30 juni 2021 09:01 :
[...]
Mullis probeert te voorkomen dat hij gelyncht wordt op de eerstvolgende vergadering...........
Prima toch zo’n actie ;)
Elk nieuws ( in dit geval afzien van bonus) hoe goed ook bedoeld wordt door beleggers als negatief ervaren en de koers wordt hierdoor omlaag geduwd. Dit soort acties van de directie zet weinig zoden aan de dijk. Ik zou zeggen los het dispuut met Uk maar op en zorg voor orders aan die kant van het water.
Cappuccino schreef op 30 juni 2021 10:18 :
[...]Prima toch zo’n actie ;)
Bedoel je het lynchen.....???
HOBBYMAN schreef op 30 juni 2021 10:36 :
Elk nieuws ( in dit geval afzien van bonus) hoe goed ook bedoeld wordt door beleggers als negatief ervaren en de koers wordt hierdoor omlaag geduwd. Dit soort acties van de directie zet weinig zoden aan de dijk. Ik zou zeggen los het dispuut met Uk maar op en zorg voor orders aan die kant van het water.
Het dispuut lijkt inderdaad het enige waar de koers op dit moment van afhankelijk is. Daar moet gewoon z.s.m. duidelijkheid over komen, al is het ook belangrijk om de tijd te nemen en tot een goede oplossing te komen.
Ronster schreef op 30 juni 2021 10:56 :
[...]
Het dispuut lijkt inderdaad het enige waar de koers op dit moment van afhankelijk is. Daar moet gewoon z.s.m. duidelijkheid over komen, al is het ook belangrijk om de tijd te nemen en tot een goede oplossing te komen.
Niet alleen het dispuut, maar ook waar gaan ze in de toekomst het geld mee verdienen. We weten dat de Corona gerelateerde inkomsten minder worden. Hoe zit het met overname plannen enz nog genoeg vragen anders dan het dispuut.
www.nu.nl/coronavirus/6142453/advies-... Koepelorganisatie GGD GHOR heeft alle regionale GGD's geadviseerd om te stoppen met de snelle antigeentest en voortaan alleen nog de PCR-test aan te bieden, zo laat een woordvoerder woensdag weten. Volgens GGD GHOR is de PCR-test in deze fase van de bestrijding van de coronapandemie beter geschikt om het virus te blijven volgen.
Ik ben eruit gestapt. Als na elk nieuw de koers omlaag gaat dan is vertrouwen geheel weg. Ik hoef geen 2e galapagos meer mee te maken. Succes aan de zittenblijvers
HOBBYMAN schreef op 30 juni 2021 17:46 :
Ik ben eruit gestapt. Als na elk nieuw de koers omlaag gaat dan is vertrouwen geheel weg. Ik hoef geen 2e galapagos meer mee te maken. Succes aan de zittenblijvers
Ik voel met je mee, aandeelhouder zijn van Novacyt is momenteel geen leuke HOBBYMAN..
Tsja. Beetje gegokt met solutions, op laag niveau. Overweeg nu wederom in Novacyt te stappen. Vrijdag immer up.
En volbracht, wederom aandeelhouder. Zodra de animo verdwijnt onstaan er nieuwe mogelijkheden.
€URO-Trader schreef op 1 juli 2021 11:49 :
En volbracht, wederom aandeelhouder. Zodra de animo verdwijnt onstaan er nieuwe mogelijkheden.
Welkom terug aan boord. Ik heb vooralsnog niks verkocht. Dat had ik veel eerder moeten doen, maar nu blij ik zitten ook.
Louis7 schreef op 1 juli 2021 10:06 :
:-))
twitter.com/gasman2020/status/1410364... Geinig! :-)
HOBBYMAN schreef op 30 juni 2021 17:46 :
Ik ben eruit gestapt. Als na elk nieuw de koers omlaag gaat dan is vertrouwen geheel weg. Ik hoef geen 2e galapagos meer mee te maken. Succes aan de zittenblijvers
Geweldige timing........!!!!
DeZwarteRidder schreef op 1 juli 2021 12:27 :
[...]
Geweldige timing........!!!!
Dankjewel. Ik hoop dat ik het begin te leren.
HOBBYMAN schreef op 29 juni 2021 19:08 :
Even recapitulatie van de laatste 2 weken.
Vorige week publicatie jaarrekening 2020.
Vandaag (conform eerdere toezegging) publicatie over nieuwe producten.
Komende week nieuwe (positieve) berichten over afhandeling dispuut met UK en nieuwe orders. Laat maar komen.
Koers zal volgens mij eind juli tussen 7 en 8 euro liggen. Watch my words!
OK - dan snap ik waarom je nu bent uitgestapt om straks tegen 7 en 8 euro weer terug te kopen, contra-shorter.
Deel 1 Dear Fellow Novacyt Shareholders Firstly thanks for your support in highlighting the concerns to the Novacyt IR Team last week. I have thought carefully about the response from Mandy and also what its implications is; I have summarised this below. I have also put forewards a plan of action at the end of the mail. I would ask you to consider supporting that moving forward. Response To Email From Novacyt On 29th June DHSC Dispute (Response Reminder): As you will be aware there are very strict stock exchange rules about disclosure and we simply cannot give one set of shareholders more information that the rest of the shareholders or the market generally do not possess. In addition, we have obligations of confidentiality with DHSC which limit severely what we can say*. Importantly, we do not wish to make public our strategy for resolving the dispute as that could undermine our negotiation leverage with DHSC. Whilst we appreciate that you would like to know more on an ongoing basis, and that you would like to support us with the dispute, we simply are not permitted to give you the detailed information you request (even yes/no answers). Again, please be assured that your questions are exactly the type of questions we consider with our legal team. As and when we have more information to give, we will update the market and all shareholders, as required and permitted by the market disclosure rules. * We are only likely to receive DHSC consent to disclosures when and if it suits them which most of the time would not in all likelihood be beneficial for the Company.
Deel 2 FIRST REASON Why I am NOT buying the response: The wording in the contract explicitly carves out: 37.1.2 the provisions of Clause 37 of this Schedule 2 shall not apply to any Confidential Information: …. (v) which the Recipient is required to disclose purely to the extent to comply with the requirements of any relevant stock exchange. And it's a requirement on Novacyt under AIM Rules General disclosure of price sensitive information 11. An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities. By way of example, this may include matters concerning a change in: …. — the performance of its business; or — its expectation of its performance. In my opinion it is an inescapable fact that the past & current performance of the business & the expected performance of the business is significantly impacted by the facts surrounding the dispute with the DHSC. Therefore I don’t agree with the assertion in the mail from Mandy Cowling that this would put them in breach of the contract. SECOND REASON Why I am not buying the response Therefore for the same reasons above it is clear that the company is OBLIGED to inform the market of the most material facts concerning the dispute in as much as the strength of the case has a material impact on past, present and future performance of the business. THIRD REASON Why I am not buying the response Part of the rationale given is that it would undermine leverage they have with the DHSC with regard to the dispute. I not only disagree but this poses a significant question of the following: The Company has stated already that it has been advised already that it has a strong case to pursue its rights under the contract; and as such these things will have been factored into that assertion. It is entirely logical then to surmise that if the company is readily, and without undue delay pursuing its rights under the contract… then the verification of exactly these facts would have to be established in order to have reached that conclusion, and should already have been presented to the DHSC as to underpin the strength of the company’s position. These items SHOULD not be a secret to the DHSC and withholding them confers no benefit to the company, to the contrary it lengthens the delay. Unless of course the company has not adequately performed its duties with regard to these material facts, and the company is acting in the ‘hope’ the have gone unnoticed, and will continue to remain so by the DHSC. This is a concerning way to be conducting a dispute with so much at stake for the business. In which case these are still material facts which would without doubt have a significant impact on the outcome and therefore my second point above remains. FOURTH REASON Why I am not buying the response The CEO & CFO received significant financial benefits under the LTIP, they personally would have control over information provided to the markets; the company could conceivably have not disclosed information which had it been in the public domain would have had a material impact on the share price of the company and the net result of which would have been: Shareholders continued to buy & hold positions in the company with information which would have had an impact on the share price, having been withheld. The CEO & CFO potentially have benefited from inflated compensation from the materialisation of these events. We as shareholders are due transparency here; IT’S OUR MONEY. This is not an accusation, it is a request for transparency. FIFTH REASON Why I am not buying the response In my mail I gave the CEO/CFO the opportunity to show they would accommodate a not unreasonable request for them to voluntarily defer payments under the LTIP until the matter is resolved. Especially given their assertion of a high degree of confidence in the outcome There was no response on this. Plan Moving Forward I will send a letter to the IR Team & GM on Monday asking them to reconsider their response in light of the above points. I will also timeframe that response as being needed before the end of business day the following Monday. IF no response is forthcoming then I will evaluate the merits of attempting to initiate an EGM to force the issue further. In order to evaluate whether the latter is feasible; I am asking if you will continue to add your support to my pursuance of this matter and also give some detail at to the size of your holding as in order to initiate such an event we would need either 5% or more of the total voting rights of all shareholders Or 100 shareholders that hold shares that have been paid up with an average of at least GB£100 per shareholder. The number of shares represented would in any case strengthen our message. I am also deeply mindful of people’s privacy. Though I have kept communications in BC where possible; I can’t guarantee that Novacyt will do the same, (Mandy already failed that test). So to maximise support am asking if you could complete the form here: forms.gle/FUdLDr7GKMTJV25c6 It will take less than a minute and your information will be held securely and not shared other than for the purposes intended now without your consent. If you do not wish to take part simply don’t complete. I hasten to add, at this stage I would initiate only step 1 above; also that this is not an accusation of any wrongdoing on behalf of Novacyt or any of its officers or employees; it is simply a group of shareholders asserting clarity on the position of the company under the auspices of what they believe to be their rights. An commentable version of the above positions is available at docs.google.com/document/d/1x542_-Zsm... Also I hasten to add that I am no expert in these matters, I remain open to your advice and thoughts on the matter. Feel free to post to me either on the form or via email directly and I will share as appropriate. I would ask you please to use the form as there's over 50 people on this initial communications; I suspect the number to grow and please be mindful I am volunteering my time as SUPPORTER of Novacyt. Feel free to forward this email to other holders you may know; I will be posting on The Telegram Group I am a member of plus to some other shareholders, Ill hold back from LSE as its a place where trolls and derampers lurk. I am avoiding putting it on the main twitter feed at the moment, I would ask you to do the same. My sincerest hope is it does not come to that and we get the assurances we need, or even better the issue gets resolved, for which though I am not holding my breath but also nor am I happy to wait blindly for. Kind regards & GLA Dunc
Voor zij die hieraan willen meedoen, hier de link om in te schrijven : Just reminder please show your support here forms.gle/Gur7UVY3e3iU5dNSA Great as it is to hear views I am also mindful of the Reply To All Function and our respective email boxes. I should have sent to all in BC first time and apologise for that mistake. Cheers Duncan
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee